Last updated: September 5, 2026
AmBisome, the branded liposomal formulation of amphotericin B, is a mature hospital anti-infective with durable clinical demand and limited direct substitution. Its commercial value is driven less by patent exclusivity than by manufacturing complexity, specialist use, public-health procurement, and the clinical advantage of reduced nephrotoxicity compared with conventional amphotericin B. Gilead Sciences does not separately disclose AmBisome revenue, reporting it within broader product categories. The product remains commercially relevant in invasive fungal infections, febrile neutropenia, visceral leishmaniasis, cryptococcal disease, and outbreak-driven treatment demand.
What is AmBisome and how does it generate revenue?
AmBisome is liposomal amphotericin B for injection. The product packages amphotericin B in unilamellar liposomes composed primarily of hydrogenated soy phosphatidylcholine, cholesterol, and distearoyl phosphatidylglycerol. This delivery system changes the drug's distribution and tolerability profile.
The commercial proposition is clinical rather than molecular. Conventional amphotericin B is effective but associated with infusion reactions, renal toxicity, electrolyte abnormalities, and treatment-limiting adverse events. AmBisome generally commands a premium because hospitals and public-health programs value its lower renal toxicity and dosing flexibility.
The principal revenue channels are:
- Hospital purchases for invasive fungal infections.
- Government and nongovernmental procurement for visceral leishmaniasis.
- HIV and cryptococcal meningitis programs.
- Empiric antifungal therapy in high-risk neutropenic patients.
- Emergency procurement during fungal outbreaks and supply shortages.
Gilead acquired AmBisome through its 1999 acquisition of Nexstar Pharmaceuticals. The product was already commercialized before the acquisition and has since occupied a mature-product position in Gilead's portfolio.
What diseases and markets support AmBisome demand?
AmBisome demand is geographically diversified but concentrated in specialist hospitals and public-health programs.
Invasive fungal infections
In the United States and other high-income markets, the principal use cases include refractory or intolerant systemic fungal infections and empiric therapy for febrile neutropenic patients. Patients with hematologic malignancies, stem-cell transplants, solid-organ transplants, and intensive-care exposure are the core hospital population.
AmBisome competes with newer triazoles and echinocandins. It retains value where:
- Broad-spectrum activity is needed.
- Resistance limits azole use.
- A rapid fungicidal effect is preferred.
- Drug interactions make azoles less attractive.
- Renal toxicity must be reduced relative to conventional amphotericin B.
Visceral leishmaniasis
Liposomal amphotericin B is a major treatment option for visceral leishmaniasis. Demand is concentrated in India, Bangladesh, Nepal, East Africa, and other endemic regions. The market is heavily influenced by government tenders, World Health Organization guidance, donor financing, and country-specific treatment protocols.
AmBisome has been used in elimination programs because of its efficacy and shorter-course potential. The price and supply structure in these markets differ materially from U.S. hospital pricing. Gilead has supported access programs that supplied the product at reduced prices or through donations in selected endemic countries.
Cryptococcal meningitis
WHO guidelines recommend a single high dose of liposomal amphotericin B as part of preferred induction treatment for HIV-associated cryptococcal meningitis, combined with flucytosine and fluconazole where available. This recommendation expands the strategic importance of liposomal amphotericin B in global HIV care, although actual demand depends on diagnostic capacity, antifungal availability, and national procurement budgets (World Health Organization, 2022).
Outbreak-driven demand
AmBisome demand can rise sharply during regional fungal outbreaks. India experienced a major surge in mucormycosis cases during the COVID-19 pandemic, creating acute demand for amphotericin B products and contributing to reported shortages. Such episodes can produce temporary revenue increases but do not establish a stable long-term growth trend.
How large is AmBisome revenue and what is its financial trajectory?
Gilead does not report AmBisome as a standalone revenue line in its annual reports. The product is included in broader product groupings that contain several mature or specialty medicines. As a result, investors cannot calculate AmBisome revenue, gross margin, or year-over-year growth directly from Gilead's public financial statements.
The financial trajectory is best characterized as mature and defensible rather than high growth.
| Financial factor |
Effect on AmBisome |
| Product age |
Limits price-based growth and patent leverage |
| Hospital use |
Supports recurring demand |
| Manufacturing complexity |
Restricts rapid competitor entry |
| Public procurement |
Creates volume but compresses price |
| Outbreak demand |
Produces episodic revenue spikes |
| New antifungal competition |
Limits expansion in routine use |
| Gilead disclosure |
Prevents standalone revenue analysis |
| Global access programs |
Supports volume but can reduce realized price |
AmBisome's economic profile differs from Gilead's major growth products, including Biktarvy, Descovy, and oncology products. It is unlikely to materially influence consolidated Gilead revenue. Its value is more consistent with a cash-generating mature product that has established clinical demand and relatively limited promotional requirements.
The main financial risks are price erosion, procurement substitution, generic competition, supply interruptions, and declining use where newer antifungals provide a safer or more convenient alternative. The principal upside is sustained global demand for liposomal amphotericin B in settings where treatment guidelines favor it.
When does AmBisome lose exclusivity?
AmBisome's core regulatory and formulation exclusivity has expired. The product was approved by the FDA in 1997, and the patents associated with its early liposomal formulation technology were filed primarily in the 1980s and 1990s. Those patents have reached the end of their ordinary U.S. terms, subject to any applicable patent-term adjustments or extensions.
The commercial consequences are important:
- AmBisome is no longer protected by a conventional new-drug patent moat.
- Generic applicants can pursue abbreviated new drug applications.
- Competitive barriers have shifted from patent rights to formulation, manufacturing, quality, supply, and regulatory execution.
- Gilead's brand retains value through hospital familiarity, clinical experience, procurement relationships, and perceived supply reliability.
The FDA Orange Book is the relevant source for current listed patents and regulatory exclusivities. AmBisome's market position is not dependent on a current period of new chemical entity exclusivity. Any remaining commercial protection would arise mainly from manufacturing know-how, trade secrets, quality systems, supplier relationships, and market access rather than from an unexpired core patent.
How many patents protect AmBisome today?
No meaningful current patent estate appears to protect the basic AmBisome product as a market exclusivity asset. The historical patent portfolio covered liposomal amphotericin compositions, drug-loading methods, lipid components, and related pharmaceutical formulations. Those rights were filed too early to provide an active long-term barrier in the current market.
The remaining IP risk is more likely to involve:
- Manufacturing processes.
- Lipid raw-material specifications.
- Sterile fill-finish procedures.
- Particle-size and encapsulation controls.
- Stability and release testing.
- Device or container configurations.
- Improvements to alternative liposomal amphotericin formulations.
These rights may complicate manufacturing without preventing all generic competition. A competitor can potentially design around process claims while still facing substantial technical and regulatory requirements.
What formulations are protected by AmBisome technology?
The central technical barrier is not the amphotericin B molecule. It is the reproducible manufacture of a stable injectable liposomal product.
Key quality attributes include:
- Liposome size distribution.
- Amphotericin B encapsulation efficiency.
- Free-drug content.
- Lipid composition and purity.
- Sterility and endotoxin control.
- Particle aggregation.
- Shelf stability.
- Reconstitution performance.
- Infusion compatibility.
Liposomal injectables are more difficult to reproduce than conventional small-molecule injections. Minor variations in lipid composition, hydration, mixing, sterilization, or storage can alter pharmacokinetics, toxicity, and clinical performance.
This manufacturing burden creates a practical barrier after patent expiration. It also makes the product vulnerable to shortages if a limited number of facilities can produce the formulation at commercial scale.
Which companies challenge AmBisome in the market?
Competition comes from both direct liposomal amphotericin products and alternative antifungal drugs.
| Competitor category |
Representative products or companies |
Competitive effect |
| Liposomal amphotericin B |
Generic manufacturers, including regional injectable specialists |
Direct price and volume competition |
| Conventional amphotericin B |
Generic amphotericin B deoxycholate |
Lower acquisition cost, higher toxicity burden |
| Lipid complex amphotericin B |
Abelcet and related products |
Alternative lipid-based formulation |
| Triazoles |
Voriconazole, isavuconazole, posaconazole, itraconazole |
Compete in invasive mold and yeast infections |
| Echinocandins |
Micafungin, caspofungin, anidulafungin |
Compete in candidiasis and selected empiric settings |
| Global suppliers |
Cipla, Sun Pharma, Fresenius Kabi, Dr. Reddy's and others depending on jurisdiction |
Increase regional sourcing options |
The direct competitive landscape varies by country. A product approved in India, Europe, or another market may not be approved or commercially available in the United States. Generic entry also depends on whether the applicant can demonstrate pharmaceutical equivalence and satisfy FDA expectations for a complex liposomal injectable.
What is the FDA regulatory status of AmBisome?
AmBisome is FDA-approved as an injectable liposomal formulation of amphotericin B. The approved U.S. labeling includes treatment of systemic fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy, empiric treatment of presumed fungal infections in febrile neutropenic patients, and treatment of visceral leishmaniasis in the applicable label framework (U.S. Food and Drug Administration, 2023).
The product is regulated as a drug, not a biologic. Biosimilar rules therefore do not apply. Any competitor would use a generic drug pathway, generally an ANDA, or another applicable abbreviated pathway.
Are there AmBisome biosimilar risks?
No. AmBisome is not a biologic and does not face biosimilar competition. The relevant risk is generic competition involving a complex injectable formulation.
The regulatory challenge is greater than for a simple aqueous injection because the generic must match critical attributes of the liposomal product. This can slow approvals, raise development costs, and reduce the number of commercially viable entrants.
What Paragraph IV challenges and litigation affect AmBisome?
Because the core AmBisome patent position is mature, Paragraph IV litigation is not the primary current market issue. A Paragraph IV certification would be relevant only if a generic applicant challenged an unexpired patent listed in the Orange Book.
The principal litigation risk is therefore lower than for recently launched medicines with active formulation or method-of-use patents. The more material risks are:
- ANDA approval timing.
- FDA manufacturing inspections.
- Product quality observations.
- Supply continuity.
- Generic product launch economics.
- Contracting and hospital formulary placement.
No active, commercially determinative Paragraph IV litigation is necessary to explain AmBisome's current competitive position. Its exposure is primarily operational and commercial rather than litigation-driven.
What generic entry risks exist for AmBisome?
Generic entry is possible, but entry does not guarantee rapid or complete substitution.
Generic launch scenario
A likely base-case scenario is gradual multi-source competition:
- One or more generic liposomal amphotericin products obtain approval.
- Hospitals adopt them first in price-sensitive tenders.
- Brand retention is stronger in institutions prioritizing established supply and clinical familiarity.
- Prices decline in procurement markets.
- Supply disruptions create periodic share reversals between brand and generics.
A more aggressive scenario would involve several approved suppliers and significant tender substitution. That could produce meaningful AmBisome price erosion, especially in public-health markets.
A constrained-entry scenario would result if only a small number of manufacturers sustain approval and reliable supply. In that case, AmBisome could preserve premium pricing despite patent expiry.
How does AmBisome compare with conventional amphotericin B and newer antifungals?
| Attribute |
AmBisome |
Conventional amphotericin B |
Newer triazoles and echinocandins |
| Main advantage |
Lower renal toxicity and broad activity |
Low acquisition cost |
Targeted use and improved tolerability in selected settings |
| Main disadvantage |
High cost and complex manufacturing |
Nephrotoxicity and infusion reactions |
Resistance, interactions, spectrum limits, or IV administration |
| Delivery |
Intravenous liposomal injection |
Intravenous infusion |
Oral or intravenous depending on product |
| Patent position |
Mature, largely expired |
Mature generic market |
Varies by product |
| Procurement status |
Premium or tender-dependent |
Low-cost baseline |
Often premium or indication-specific |
| Global-health role |
Strong in leishmaniasis and cryptococcal disease |
Limited by toxicity |
Increasing in selected infections |
AmBisome remains differentiated where safety and broad activity justify a premium. It is less attractive when a hospital can use an effective oral triazole or low-cost conventional amphotericin B without unacceptable toxicity.
What licensing and access agreements influence AmBisome sales?
Gilead's commercial model has included access initiatives for endemic diseases, particularly visceral leishmaniasis. These arrangements support public-health use but can lower average selling prices compared with high-income hospital markets.
The key commercial structure is a two-tier market:
- High-income markets generate higher prices with lower volumes.
- Endemic-country programs generate larger public-health volumes at reduced prices or through donation mechanisms.
This structure supports global clinical penetration but limits the direct translation of increased unit volume into revenue growth.
What geographic markets matter most for AmBisome?
The United States and Europe are important for invasive fungal infections and specialized hospital care. India is strategically important because of visceral leishmaniasis, a large hospital market, and episodic mucormycosis demand. East Africa remains important for visceral leishmaniasis and HIV-related fungal disease.
Geographic performance depends on:
- National treatment guidelines.
- Hospital antifungal budgets.
- Donor and procurement funding.
- Generic availability.
- Local manufacturing.
- Disease incidence.
- Supply continuity.
AmBisome's exposure is therefore global but fragmented. No single country fully determines the product's long-term trajectory.
How strong is the AmBisome commercial and patent estate?
The patent estate is weak as a current exclusivity mechanism. The commercial estate is stronger because of clinical familiarity, regulatory history, physician confidence, and the difficulty of manufacturing a consistent liposomal injectable.
| Estate component |
Assessment |
| Core molecule |
Weak protection; amphotericin B is generic |
| Core formulation patents |
Largely expired |
| Regulatory exclusivity |
Expired |
| Brand recognition |
Strong in specialist antifungal care |
| Manufacturing barrier |
Moderate to high |
| Clinical differentiation |
Strong versus conventional amphotericin B |
| Generic substitution risk |
Moderate |
| Revenue growth potential |
Low to moderate |
| Revenue durability |
Moderate to high if supply remains reliable |
Key Takeaways
- AmBisome is a mature liposomal amphotericin B product owned and commercialized by Gilead Sciences.
- Its principal advantages are lower renal toxicity, broad antifungal activity, and established use in global-health programs.
- Core patent and regulatory exclusivity have expired; current value comes from manufacturing complexity and market position.
- Gilead does not disclose standalone AmBisome revenue, preventing a precise product-level financial model.
- Revenue is likely stable to modestly declining in routine use, with temporary increases during fungal outbreaks or supply shortages.
- Generic competition is the main long-term commercial threat, but complex injectable manufacturing limits the number of reliable entrants.
- Biosimilar competition is irrelevant because AmBisome is a conventional drug, not a biologic.
- The strongest demand areas are invasive fungal infections, visceral leishmaniasis, cryptococcal meningitis, and high-risk neutropenic care.
- Public-health procurement expands patient access but produces lower realized prices.
- Supply reliability, quality control, and hospital contracting are more important than Paragraph IV litigation in the current market.
FAQs About AmBisome Market Outlook
Is AmBisome still patent protected?
The core AmBisome formulation and drug patents are mature, and the product no longer depends on new chemical entity exclusivity. Current protection is more likely to arise from manufacturing know-how than from broad active patents.
Can generic manufacturers launch liposomal amphotericin B?
Yes. Generic entry is legally possible, but the product is technically difficult to manufacture and requires control of complex liposomal quality attributes.
Is AmBisome more effective than conventional amphotericin B?
Both contain amphotericin B, but AmBisome generally has a more favorable renal and infusion-related tolerability profile. Clinical selection depends on disease, patient risk, treatment protocol, and cost.
Does AmBisome compete with Cresemba and Vfend?
Yes. Isavuconazole, voriconazole, and other triazoles compete with AmBisome in selected invasive fungal infections. They do not provide a complete substitute across all AmBisome indications.
Will AmBisome revenue grow materially for Gilead?
Material growth is unlikely based on the product's mature status, undisclosed standalone revenue, patent expiry, and competition from generics and newer antifungals. Episodic demand increases remain possible during outbreaks or supply disruptions.
References
-
Gilead Sciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. Gilead Sciences.
-
U.S. Food and Drug Administration. (2023). AmBisome (amphotericin B) liposome for injection prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. U.S. Department of Health and Human Services.
-
World Health Organization. (2022). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. World Health Organization.
-
World Health Organization. (2022). WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. World Health Organization.
